Over the past seven years, a top editor at a medical journal devoted to obesity research received $1.2 million from companies that sold or were developing prescription weight-loss treatments, raising concerns about how potential conflicts of interest among those with especially influential roles in academic publishing are treated.
During that time, Obesity associate editor-in-chief Donna Ryan co-authored a paper describing the added benefits of a diabetes treatment sold by a company that paid her the bulk of those fees. The same company paid a communications firm to provide writing assistance. She also co-authored an editorial praising the pricing approach taken by a manufacturer with which she had a financial relationship, although the effectiveness of the diet drug was modest. Unlike the paper, the editorial did not disclose her ties.
What is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Create a display name to comment
This name will appear with your comment